LEADER 01059cam0-22003731i-450- 001 990000838550403321 005 20060222101405.0 035 $a000083855 035 $aFED01000083855 035 $a(Aleph)000083855FED01 035 $a000083855 100 $a20020821d1970----km-y0itay50------ba 101 0 $aeng 102 $aUS 105 $ay-------001yy 200 1 $aLinear partial differential equations$fFrançois Trèves 210 $aNew York$cGordon & Breach$d1970 215 $aX, 120 p.$d24 cm 225 1 $aNotes on mathematics and its applications 610 0 $aEquazioni differenziali e integro$aDifferenziali 676 $a515.353 676 $a517.37 700 1$aTreves,$bFrançois$f<1930- >$0424171 801 0$aIT$bUNINA$gRICA$2UNIMARC 901 $aBK 912 $a990000838550403321 952 $a02 29 E 10$b628$fFINBN 952 $a15-097$b6461 F.T.$fFI1 952 $a26-G-4$b11011$fMA1 959 $aFINBN 959 $aMA1 959 $aFI1 996 $aLinear partial differential equations$982336 997 $aUNINA LEADER 01066cam--2200373---450 001 990003511010203316 005 20201116110925.0 010 $a978-88-6159-505-7 035 $a000351101 035 $aUSA01000351101 035 $a(ALEPH)000351101USA01 035 $a000351101 100 $a20110307d2010----km-y0itay50------ba 101 1 $aita$ceng 102 $aIT 105 $aa---||||001yy 200 1 $aCarlomagno$ebarbaro e imperatore$fDerek Wilson 210 $a[Milano]$cBruno Mondadori$d2010 215 $a291 p.$cill.$d24 cm 225 2 $a<> storia narrata 300 $aTraduzione di Valentina Ricci 410 0$12001$a<> storia narrata 454 0$12001$aCharlemagne$937091 600 0$aCarlo : Magno $2BNCF 676 $a944.0142092 700 1$aWILSON,$bDerek$f<1935- >$0244556 702 1$aRICCI,$bValentina 801 0$aIT$bsalbc$gISBD 912 $a990003511010203316 951 $aX.1.B. 1356$b230471 L.M.$cX.1.B.$d00165237 959 $aBK 969 $aUMA 996 $aCharlemagne$937091 997 $aUNISA LEADER 04227nam 22006735 450 001 9910298346303321 005 20260415135654.0 010 $a3-319-08162-4 024 7 $a10.1007/978-3-319-08162-5 035 $a(CKB)3710000000261984 035 $a(EBL)1967221 035 $a(OCoLC)896834353 035 $a(SSID)ssj0001372161 035 $a(PQKBManifestationID)11753108 035 $a(PQKBTitleCode)TC0001372161 035 $a(PQKBWorkID)11301529 035 $a(PQKB)10959862 035 $a(MiAaPQ)EBC1967221 035 $a(DE-He213)978-3-319-08162-5 035 $a(PPN)182096580 035 $a(EXLCZ)993710000000261984 100 $a20141013d2014 u| 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$amiRNAs and Target Genes in Breast Cancer Metastasis /$fby Seema Sethi 205 $a1st ed. 2014. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2014. 215 $a1 online resource (83 p.) 225 1 $aSpringerBriefs in Cancer Research,$x2194-1173 300 $aDescription based upon print version of record. 311 08$a3-319-08161-6 320 $aIncludes bibliographical references at the end of each chapters and index. 327 $aRole of miRNAs and their Target Genes in Breast Cancer Metastasis -- Molecular Pathogenesis of Breast Cancer and the Role of MicroRNAs -- Epidemiology, Risk Factors, Treatment and Prevention of Breast Cancer Metastases -- Clinical Perspectives: Breast Cancer Brain Metastasis -- Molecular targeted therapy for brain metastatic breast cancers: Current Updates. 330 $aThis SpringerBrief gives the latest research on the role of miRNAs in breast cancer metastasis. MicroRNAs (miRNAs) are recently described small endogenous noncoding RNAs implicated in the posttranscriptional control of gene expression. These tiny molecules are involved in developmental, physiologic phenomenon as well as pathologic processes including cancers. In fact, miRNAs have emerged as critical regulators of cancer progression, invasion and metastasis. This is mainly because a single miRNA can affect several downstream genes and signaling pathways with oncogenic or tumor suppressor actions depending on the target genes affected. Due to this multimodal downstream signaling effects, these small endogenous molecules hold great promise in metastasis prevention and treatment. Modulating the activity of miRNAs can provide opportunities for novel cancer interventions. Targeting miRNAs could become a novel prognostic and therapeutic strategy to prevent the future development of metastasis. Thus, miRNAs could also serve as a potential targets for anti-metastatic therapy.   The book explores how the expression of miRNAs in the primary tumor could be silenced using antagomirs (chemically modified anti-miRNA oligonucleotides), which could prevent the development of metastasis; whereas once metastasis develops then it could be treated with miRNA mimics for inducing its expression for the treatment. Therefore, development of miRNA-based prophylactic therapies could serve as precision and personalized medicine against future development of metastasis of breast and other cancers. 410 0$aSpringerBriefs in Cancer Research,$x2194-1173 606 $aCancer$xResearch 606 $aGene expression 606 $aOncology 606 $aCancer Research$3https://scigraph.springernature.com/ontologies/product-market-codes/B11001 606 $aGene Expression$3https://scigraph.springernature.com/ontologies/product-market-codes/B12010 606 $aOncology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33160 615 0$aCancer$xResearch. 615 0$aGene expression. 615 0$aOncology. 615 14$aCancer Research. 615 24$aGene Expression. 615 24$aOncology. 676 $a610 676 $a611.01816 676 $a614.5999 676 $a616994 700 $aSethi$b Seema$4aut$4http://id.loc.gov/vocabulary/relators/aut$01064622 906 $aBOOK 912 $a9910298346303321 996 $aMiRNAs and Target Genes in Breast Cancer Metastasis$92539481 997 $aUNINA